Log in

NYSE:BMYBristol-Myers Squibb Stock Price, Forecast & News

+1.31 (+2.12 %)
(As of 08/12/2020 04:00 PM ET)
Today's Range
Now: $63.13
50-Day Range
MA: $59.11
52-Week Range
Now: $63.13
Volume20.74 million shs
Average Volume15.16 million shs
Market Capitalization$142.84 billion
P/E RatioN/A
Dividend Yield2.85%
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Read More
Bristol-Myers Squibb logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$26.15 billion
Cash Flow$4.48 per share
Book Value$21.73 per share


Net Income$3.44 billion


Outstanding Shares2,262,690,000
Market Cap$142.84 billion
Next Earnings Date10/29/2020 (Estimated)
+1.31 (+2.12 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

How has Bristol-Myers Squibb's stock been impacted by Coronavirus (COVID-19)?

Bristol-Myers Squibb's stock was trading at $56.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BMY shares have increased by 11.7% and is now trading at $63.13.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Bristol-Myers Squibb?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bristol-Myers Squibb

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Bristol-Myers Squibb

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) released its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.48 by $0.15. The biopharmaceutical company earned $10.13 billion during the quarter, compared to the consensus estimate of $10.04 billion. Bristol-Myers Squibb had a positive return on equity of 28.47% and a negative net margin of 1.61%. Bristol-Myers Squibb's revenue for the quarter was up 61.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.18 EPS.
View Bristol-Myers Squibb's earnings history

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Thursday, June 11th. Stockholders of record on Monday, July 6th will be paid a dividend of $0.45 per share on Monday, August 3rd. This represents a $1.80 annualized dividend and a dividend yield of 2.85%. The ex-dividend date is Thursday, July 2nd.
View Bristol-Myers Squibb's dividend history

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY20 earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of $6.10-6.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.22. The company issued revenue guidance of $40.5-42.0 billion, compared to the consensus revenue estimate of $42.00 billion.

What price target have analysts set for BMY?

16 brokerages have issued twelve-month price targets for Bristol-Myers Squibb's stock. Their forecasts range from $50.00 to $88.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $69.29 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price.
View analysts' price targets for Bristol-Myers Squibb

Has Bristol-Myers Squibb been receiving favorable news coverage?

Press coverage about BMY stock has trended extremely negative on Thursday, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bristol-Myers Squibb earned a news impact score of -4.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about Bristol-Myers Squibb

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 33,050,000 shares, an increase of 20.4% from the March 31st total of 27,440,000 shares. Based on an average daily volume of 16,340,000 shares, the short-interest ratio is currently 2.0 days.
View Bristol-Myers Squibb's Short Interest

Who are some of Bristol-Myers Squibb's key competitors?

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), NVIDIA (NVDA), Verizon Communications (VZ), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), CVS Health (CVS) and Bank of America (BAC).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the following people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 54)
  • Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
  • Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)
  • Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)
  • Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57)

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.47%), Swiss National Bank (0.40%), Prudential Financial Inc. (0.24%), New York State Common Retirement Fund (0.23%), Principal Financial Group Inc. (0.17%) and New York State Teachers Retirement System (0.15%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Dinesh C Paliwal, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini and Theodore R Samuels II.
View institutional ownership trends for Bristol-Myers Squibb

Which institutional investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, First Trust Advisors LP, Railway Pension Investments Ltd, Sumitomo Mitsui Trust Holdings Inc., Pzena Investment Management LLC, New York State Common Retirement Fund, Smith Asset Management Group LP, and Amalgamated Bank. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, John E Elicker, and Louis S Schmukler.
View insider buying and selling activity for Bristol-Myers Squibb

Which institutional investors are buying Bristol-Myers Squibb stock?

BMY stock was bought by a variety of institutional investors in the last quarter, including AJO LP, Bank of Nova Scotia, Unigestion Holding SA, Todd Asset Management LLC, Cannell Peter B & Co. Inc., Adams Diversified Equity Fund Inc., Sabal Trust CO, and South Street Advisors LLC. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini, and Theodore R Samuels II.
View insider buying and selling activity for Bristol-Myers Squibb

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $63.13.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $142.84 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 30,000 workers across the globe.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is www.bms.com.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.